Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
复制标题
DOI:
10.1161/circulationaha.118.035432
复制
发表时间:
2018-07-10
期刊:
影响因子:
37.8
通讯作者:
Ridker, Paul M.
中科院分区:
文献类型:
--
作者:
Pradhan, Aruna D.;Aday, Aaron W.;Ridker, Paul M.
Background: Despite strong and consistent prospective associations of elevated low-density lipoprotein (LDL) cholesterol concentration with incident coronary and cerebrovascular disease, data for incident peripheral artery disease (PAD) are less robust. Atherogenic dyslipidemia characterized by increased small LDL particle (LDL-P) concentration, rather than total LDL cholesterol content, along with elevated triglyceride-rich lipoproteins and low high-density lipoprotein (HDL) cholesterol (HDL-C), may be the primary lipid driver of PAD risk.Methods: The study population was a prospective cohort study of 27 888 women 45 years old free of cardiovascular disease at baseline and followed for a median of 15.1 years. We tested whether standard lipid concentrations, as well as nuclear magnetic resonance spectroscopy-derived lipoprotein measures, were associated with incident symptomatic PAD (n=110) defined as claudication and/or revascularization.Results: In age-adjusted analyses, while LDL cholesterol was not associated with incident PAD, we found significant associations for increased total and small LDL-P concentrations, triglycerides, and concentrations of very LDL (VLDL) particle (VLDL-P) subclasses, increased total cholesterol (TC):HDL-C, low HDL-C, and low HDL particle (HDL-P) concentration (all P for extreme tertile comparisons